No abstract available
Keywords:
Bone remodeling; Everolimus; Mammalian target of rapamycin (mTOR); Osteoclasts; Tuberous Sclerosis Complex 1 (TSC1).
MeSH terms
-
Aged
-
Bone Neoplasms / drug therapy*
-
Bone Neoplasms / secondary
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / pathology
-
Disease Progression
-
Humans
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / pathology
-
Male
-
Mechanistic Target of Rapamycin Complex 1
-
Multiprotein Complexes / antagonists & inhibitors
-
Protein Kinase Inhibitors / administration & dosage*
-
Protein Kinase Inhibitors / therapeutic use
-
Sirolimus / administration & dosage
-
Sirolimus / analogs & derivatives*
-
Sirolimus / therapeutic use
-
TOR Serine-Threonine Kinases / antagonists & inhibitors
-
Treatment Outcome
Substances
-
Multiprotein Complexes
-
Protein Kinase Inhibitors
-
temsirolimus
-
Mechanistic Target of Rapamycin Complex 1
-
TOR Serine-Threonine Kinases
-
Sirolimus